Download Audio
Faculty Disclosures
CME Information
Event
CME Test
banner
  Go to Debate 1 (Discussant: Dr Burstein)
Go to Debate 2 (Discussant: Dr Buzdar)
Go to Debate 3 (Discussant: Dr Hudis)
Go to Debate 4 (Discussant: Dr Dixon)
Go to Debate 5 (Discussant: Dr Vogel)
Go to Debate 6 (Discussant: Dr Mackey)
Go to Debate 7 (Discussant: Dr Tripathy)
 


To listen to individual tracks, click the on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.
   
Burstein, MD Harold J Burstein, MD, PhD
Assistant Professor of Medicine
Breast Oncology Center
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Debate 1
Agree, disagree or in between?
Most patients with ER-positive, HER2-negative, node-negative breast cancer should be presented with the option of participating in the TAILORx trial and of having the Oncotype DX™ assay performed outside of a trial.

Agree, disagree or in between?
When AC chemotherapy is utilized, dose-dense AC (no taxane) administered every two weeks with growth factor support provides the optimal potential risk/benefit profile.
Click here to listen to the entire debate 1
   
Buzdar, MD Aman U Buzdar, MD
Professor of Medicine
Deputy Chairman, Department of
Breast Medical Oncology
The University of Texas
MD Anderson Cancer Center
Houston, Texas
Debate 2
Agree, disagree or in between?
For postmenopausal women with ER-positive, metastatic disease, tamoxifen, an aromatase inhibitor or fulvestrant are essentially equivalent choices.
Click here to listen to the entire debate 2
   
Hudis, MD Clifford Hudis, MD
Chief, Breast Cancer Medicine Service
Solid Tumor Division
Memorial Sloan-Kettering
Cancer Center
New York, New York
Debate 3
Agree, disagree or in between?
Outside a protocol setting, dose-dense AC arrowpaclitaxel, administered every two weeks with growth factors, with trastuzumab during and following the paclitaxel, provides the best potential risk/benefit profile for women with HER2-positive, node-positive disease.
Click here to listen to the entire debate 3
   
Dixon, MD J Michael Dixon, MD
Consultant Surgeon and
Senior Lecturer
Academic Office
Edinburgh Breast Unit
Western General Hospital
Edinburgh, Scotland
United Kingdom
Debate 4
Agree, disagree or in between?
Neoadjuvant therapy with an aromatase inhibitor provides the best potential risk/benefit profile for postmenopausal women with HER2-negative, strongly ER-positive and PR-positive disease.
Click here to listen to the entire debate 4
   
Vogel, MD Charles L Vogel, MD
Medical Director
Cancer Research Network Inc
Boca Raton, Florida
Debate 5
Agree, disagree or in between?
Outside a protocol setting, carboplatin/docetaxel/trastuzumab followed by trastuzumab for a total duration of one year provides the best potential risk/benefit profile for elderly patients with ER-negative, PR-negative, HER2-positive, multiple node-positive breast cancer with a prior cardiac history.
Click here to listen to the entire debate 5
   
Mackey, MD John Mackey, MD
Medical Oncologist
Cross Cancer Institute
Professor, Medical and
Experimental Oncology
University of Alberta
Chair of Research, Northern Alberta
Breast Cancer Program
Director, Cancer International
Research Group
Edmonton, Canada
Debate 6
Agree, disagree or in between?
Outside a protocol setting, a combination of endocrine therapy and trastuzumab provides the best potential risk/benefit profile for women with ER-positive, HER2-positive metastatic disease.
Click here to listen to the entire debate 6
   
Tripathy, MD Debu Tripathy, MD
Professor of Internal Medicine
Director, Komen UT Southwestern
Breast Cancer Research Program
University of Texas Southwestern
Medical Center
Dallas, Texas
Debate 7
Agree, disagree or in between?
Outside a protocol setting, the combination of lapatinib and capecitabine provides the best potential risk/benefit profile for women with ER-negative, PR-negative, HER2-positive, node-positive disease with cancer recurrence after ACarrowTH.
Click here to listen to the entire debate 7